Clinical trials: Chronic Heart Disorder
End-Stage Renal Disease
Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial
The SPin-D Trial is a phase II randomized, double-blind, placebo-controlled, multi-center study of spironolactone (SPL) for patients with hemodialysis-dependent end-stage renal disease.
- Trial name
- SPin-D (NCT02285920)
- Testing
- Spironolactone
- Where
- 4 sites in United States
- Volunteers
- 129 people
- Sponsor
- University of Pennsylvania
Heart Failure, Kidney Dysfunction
The Effects of Decreasing the Lasix Dose on the Cardiorenal System
The investigators' objective is to define the effects of decreasing the furosemide dose on heart, kidney and humoral function in people with compensated heart failure and kidney dysfunction and also in people with compensated…
- Trial name
- Aim1 (NCT00982423)
- Testing
- Furosemide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Mayo Clinic
COPD, Sepsis
Effect of Nebulized Bronchodilators on Heart Rate
The purpose of the study is to determine adverse events rates of nebulized albuterol versus levalbuterol among adult critically ill patients and determine if a differential exists in adverse events between the two drugs.
- Conditions
- COPD, Sepsis, Shock
- Trial name
- NCT01151579
- Testing
- Levalbuterol, Albuterol
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Fahim Khorfan, MD
Coronary Heart Disease
Testosterone and Myocardial Perfusion in Coronary Heart Disease (CHD)
Testosterone has traditionally been regarded as a risk factor for heart disease due to the fact that males have a higher incidence of this disease than women, at least until the menopause.
- Trial name
- NCT00239590
- Testing
- Testosterone undecanoate
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- Imperial College London
Heart Failure, Congestive
Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5
The purpose of this study is to determine whether treatment with the OPTIMIZER System is safe and effective in patients with moderate to severe heart failure symptoms.
- Trial name
- NCT00112125
- Testing
- OPTIMIZER System
- Where
- United States
- Volunteers
- 428 people
- Sponsor
- Impulse Dynamics
Heart Failure, Sleep Apnea Syndromes
Oxygen Versus PAP for Sleep Apnea in Heart Failure
The purpose of this study is to compare three treatment modalities for central, or mixed obstructive and central, sleep apnea in patients with chronic heart failure and reduced ejection fraction.
- Trial name
- OPTIMAL-HF (NCT01807897)
- Testing
- Continuous positive airway pressure, Nocturnal supplemental oxygen, Healthy Lifestyle and Sleep Education
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- VA Office of Research and Development
Chronic Kidney Disease, Cardiac Disease
Low Dose Continuous Furosemide Effect on Cardiac Surgery Patients With Kidney Dysfunction
Chronic kidney disease is an independent risk factor for cardiovascular disease associated with increased mortality rate during cardiac surgery in proportion to the kidney function.
- Trial name
- NCT04919564
- Testing
- Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL), NaCl 0.9%
- Where
- Indonesia
- Volunteers
- 90 people
- Sponsor
- National Cardiovascular Center Harapan Kita Hospital Indonesia
Cardiovascular Diseases, Cardiovascular Abnormalities
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12-month (52 weeks) period in ESRD patients on HD
- Conditions
- Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease
- Trial name
- NCT02966028
- Testing
- SNF472
- Where
- 75 sites in United States, Spain and 1 more
- Volunteers
- 274 people
- Sponsor
- Sanifit Therapeutics S. A.
Heart Failure, Type 2 Diabetes Mellitus
SGLT2 Inhibition in Combination With Diuretics in Heart Failure
The RECEDE-CHF trial is a single centre phase IV, randomised, double-blind, placebo-controlled, crossover trial conducted in NHS Tayside, Scotland comparing empagliflozin 25mg, to placebo in patients with Type 2 Diabetes and mild…
- Trial name
- RECEDE-CHF (NCT03226457)
- Testing
- Empagliflozin 25mg, Frusemide
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Dundee
Chronic Kidney Diseases, Heart Attack
Chronic Kidney Disease (CKD) Platelet Study
This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys.
- Conditions
- Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
- Trial name
- NCT03649711
- Testing
- Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Turner Syndrome, Renal Insufficiency, Chronic
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.
- Conditions
- Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases, Dwarfism
- Trial name
- OPTIMA (NCT00234533)
- Testing
- Somatropin (rDNA origin)
- Where
- 45 sites in Belgium, Czechia and 12 more
- Volunteers
- 251 people
- Sponsor
- Ipsen
Mitral Regurgitation
Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)
The investigators hypothesize that beta-1 receptor blockade (ß1-RB) attenuates extracellular matrix (ECM) degradation and progressive adverse Left Ventricular (LV) remodeling and failure in the volume overload of mitral…
- Trial name
- P1A1 (NCT01052428)
- Testing
- metoprolol succinate (Toprol XL)
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Chronic Obstructive Pulmonary Disease, COPD
Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients
This mechanistic study is a single-center, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effect of dual bronchodilation with QVA149 on cardiac and lung function parameters in hyperinflated COPD…
- Trial name
- CLAIM (NCT02442206)
- Testing
- QVA149
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure With Preserved Systolic Function
Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure, disease specific biomarkers, symptoms, health status and quality of life in patients with chronic heart…
- Trial name
- PRESERVED-HF (NCT03030235)
- Testing
- Dapagliflozin 10Mg Oral Tablet
- Where
- 26 sites in United States
- Volunteers
- 324 people
- Sponsor
- Saint Luke's Health System
Chronic Kidney Disease, Left Ventricular Hypertrophy
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
To evaluate the effects of paricalcitol capsules on cardiac structure and function over 48 weeks in patients with Stage 3/4 chronic kidney disease (CKD) who had left ventricular hypertrophy (LVH).
- Trial name
- PRIMO (NCT00497146)
- Testing
- paricalcitol
- Where
- 71 sites in United States, Australia and 10 more
- Volunteers
- 227 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Heart Failure, Growth Hormone Deficiency
Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial
The aim of this study is to investigate the potential benefits of the correction of growth hormone (GH) deficiency with GH replacement therapy in patients with chronic heart failure due to left ventricular systolic dysfunction.
- Conditions
- Heart Failure, Growth Hormone Deficiency, Ischemic Heart Disease
- Trial name
- NCT00591760
- Testing
- Somatotropin
- Volunteers
- 56 people
- Sponsor
- Federico II University
Myocardial Ischemia
ACT34-CMI -- Adult Autologous CD34+ Cells
The purpose of this study is to evaluate the efficacy and safety of intramyocardial injections of CLBS14 in patients with refractory chronic myocardial ischemia.
- Trial name
- NCT00300053
- Testing
- CLBS14 (low-dose), CLBS14 (high-dose)
- Where
- 26 sites in United States
- Volunteers
- 321 people
- Sponsor
- Lisata Therapeutics, Inc.
Heart Failure, Congestive
Effect of Chronic Changes in Heart Rate on Congestive Heart Failure
This will be a double blind randomized crossover study of patients with congestive heart failure and a heart rate dependent upon a permanent pacemaker.
- Trial name
- NCT00389649
- Testing
- heart rate setting
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Maryland, Baltimore
Chronic Heart Failure
Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology
Targeted population: Patients with heart failure causing hospitalization during the last twelve months. Hypothesis: The number of all cause deaths and hospitalizations will be smaller for the Telecardiology group than for the…
- Trial name
- OSICAT (NCT02068118)
- Testing
- Telecardiology program
- Where
- 38 sites in France, Martinique
- Volunteers
- 990 people
- Sponsor
- CDM e-Health
Asthma, Chronic Obstructive Pulmonary Disease
Usability and Acceptability Study of the P-STEP Mobile Application
Assess the usability and acceptance of the P-STEP app, through allowing participants with specific chronic conditions to pilot the app for 12-weeks.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Coronary Heart Disease
- Trial name
- NCT05830318
- Testing
- P-STEP Mobile Application
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- University of Leicester